Literature DB >> 17401366

Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.

Julius Gudmundsson1, Patrick Sulem, Andrei Manolescu, Laufey T Amundadottir, Daniel Gudbjartsson, Agnar Helgason, Thorunn Rafnar, Jon T Bergthorsson, Bjarni A Agnarsson, Adam Baker, Asgeir Sigurdsson, Kristrun R Benediktsdottir, Margret Jakobsdottir, Jianfeng Xu, Thorarinn Blondal, Jelena Kostic, Jielin Sun, Shyamali Ghosh, Simon N Stacey, Magali Mouy, Jona Saemundsdottir, Valgerdur M Backman, Kristleifur Kristjansson, Alejandro Tres, Alan W Partin, Marjo T Albers-Akkers, Javier Godino-Ivan Marcos, Patrick C Walsh, Dorine W Swinkels, Sebastian Navarrete, Sarah D Isaacs, Katja K Aben, Theresa Graif, John Cashy, Manuel Ruiz-Echarri, Kathleen E Wiley, Brian K Suarez, J Alfred Witjes, Mike Frigge, Carole Ober, Eirikur Jonsson, Gudmundur V Einarsson, Jose I Mayordomo, Lambertus A Kiemeney, William B Isaacs, William J Catalona, Rosa B Barkardottir, Jeffrey R Gulcher, Unnur Thorsteinsdottir, Augustine Kong, Kari Stefansson.   

Abstract

Prostate cancer is the most prevalent noncutaneous cancer in males in developed regions, with African American men having among the highest worldwide incidence and mortality rates. Here we report a second genetic variant in the 8q24 region that, in conjunction with another variant we recently discovered, accounts for about 11%-13% of prostate cancer cases in individuals of European descent and 31% of cases in African Americans. We made the current discovery through a genome-wide association scan of 1,453 affected Icelandic individuals and 3,064 controls using the Illumina HumanHap300 BeadChip followed by four replication studies. A key step in the discovery was the construction of a 14-SNP haplotype that efficiently tags a relatively uncommon (2%-4%) susceptibility variant in individuals of European descent that happens to be very common (approximately 42%) in African Americans. The newly identified variant shows a stronger association with affected individuals who have an earlier age at diagnosis.

Entities:  

Mesh:

Year:  2007        PMID: 17401366     DOI: 10.1038/ng1999

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  422 in total

1.  Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection.

Authors:  Lucinda Hughes; Fang Zhu; Eric Ross; Laura Gross; Robert G Uzzo; David Y T Chen; Rosalia Viterbo; Timothy R Rebbeck; Veda N Giri
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-12-05       Impact factor: 4.254

2.  Genetic variation at chromosome 8q24 in osteosarcoma cases and controls.

Authors:  Lisa Mirabello; Sonja I Berndt; Guillermo F Seratti; Laurie Burdett; Meredith Yeager; Salma Chowdhury; Kedest Teshome; Arinze Uzoka; Chester Douglass; Richard B Hayes; Robert N Hoover; Sharon A Savage
Journal:  Carcinogenesis       Date:  2010-06-07       Impact factor: 4.944

3.  What is a functional locus? Understanding the genetic basis of complex phenotypic traits.

Authors:  Edward A Ruiz-Narváez
Journal:  Med Hypotheses       Date:  2011-02-01       Impact factor: 1.538

4.  Association of prostate cancer risk alleles with unfavourable pathological characteristics in potential candidates for active surveillance.

Authors:  Barry B McGuire; Brian T Helfand; Shilajit Kundu; Qiaoyan Hu; Jessica A Banks; Phillip Cooper; William J Catalona
Journal:  BJU Int       Date:  2011-11-11       Impact factor: 5.588

5.  Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis.

Authors:  Sarah M Troutman; Tristan M Sissung; Cheryl D Cropp; David J Venzon; Shawn D Spencer; Bamidele A Adesunloye; Xuan Huang; Fatima H Karzai; Douglas K Price; William D Figg
Journal:  Oncologist       Date:  2012-03-01

6.  Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis.

Authors:  Chiara Grisanzio; Lillian Werner; David Takeda; Bisola C Awoyemi; Mark M Pomerantz; Hiroki Yamada; Prasanna Sooriakumaran; Brian D Robinson; Robert Leung; Anna C Schinzel; Ian Mills; Helen Ross-Adams; David E Neal; Masahito Kido; Toshihiro Yamamoto; Gillian Petrozziello; Edward C Stack; Rosina Lis; Philip W Kantoff; Massimo Loda; Oliver Sartor; Shin Egawa; Ashutosh K Tewari; William C Hahn; Matthew L Freedman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-22       Impact factor: 11.205

7.  In vivo exploration of the functional activity of the non-coding 8q24 prostate cancer risk locus.

Authors:  Dolores J Lamb; Mounia Tannour-Louet
Journal:  Asian J Androl       Date:  2010-09-06       Impact factor: 3.285

Review 8.  "Higher order" addiction molecular genetics: convergent data from genome-wide association in humans and mice.

Authors:  George R Uhl; Tomas Drgon; Catherine Johnson; Oluwatosin O Fatusin; Qing-Rong Liu; Carlo Contoreggi; Chuan-Yun Li; Kari Buck; John Crabbe
Journal:  Biochem Pharmacol       Date:  2007-07-25       Impact factor: 5.858

9.  An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility.

Authors:  Joan P Breyer; Daniel C Dorset; Travis A Clark; Kevin M Bradley; Tiina A Wahlfors; Kate M McReynolds; William H Maynard; Sam S Chang; Michael S Cookson; Joseph A Smith; Johanna Schleutker; William D Dupont; Jeffrey R Smith
Journal:  Am J Hum Genet       Date:  2014-02-27       Impact factor: 11.025

10.  Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort.

Authors:  Chee L Goh; Edward J Saunders; Daniel A Leongamornlert; Malgorzata Tymrakiewicz; Karen Thomas; Elizabeth D Selvadurai; Ruth Woode-Amissah; Tokhir Dadaev; Nadiya Mahmud; Elena Castro; David Olmos; Michelle Guy; Koveela Govindasami; Lynne T O'Brien; Amanda L Hall; Rosemary A Wilkinson; Emma J Sawyer; Ali Amin Al Olama; Douglas F Easton; Zsofia Kote-Jarai; Chris C Parker; Rosalind A Eeles
Journal:  BJU Int       Date:  2013-01-15       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.